Compare Autodesk Inc (ADSK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Incyte Corporation — how do they compare? Autodesk Inc trades at $248.76 (market cap $53.12B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Autodesk Inc is far larger — about 2.2× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | INCY | |
|---|---|---|
Market Cap | $53.12B | $24.54B |
Sector | Technology | Health |
52-Week High | $326.79 | $129.93 |
52-Week Low | $187.72 | $81.61 |
Enterprise Value | $52.92B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.55, down 2.55% today, but maintains a strong fundamental profile with robust earnings beats, including Q1 2026 EPS of $2.99 versus $2.84 expected. The stock exhibits a bullish technical trend with moving averages supporting upside, though RSI levels indicate potential overbought conditions. Revenue growth is steady, projected to reach $7.5B in 2026, with a high net income margin of 19.49% in 2025.
The outlook remains positive given analyst consensus favoring Buy ratings (74.51%) and a $302.23 price target, implying significant upside. Key risks include competitive pressures in design software and reliance on enterprise spending cycles. Continued execution on AI investments and margin expansion are critical for sustaining valuation multiples.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
